Literature DB >> 3409797

Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis.

C Merkel1, A Gatta, M Bolognesi, G Finucci, G Battaglia, P Angeli, R Zuin.   

Abstract

Triglycyl-lysin-vasopressin is a long-acting vasopressin derivative which is under consideration for the treatment of acute variceal bleeding in cirrhosis. However, its splanchnic hemodynamic effects have not been investigated thoroughly. In 11 patients with alcoholic cirrhosis, systemic and splanchnic hemodynamics were evaluated before and 20-40 min after intravenous administration of 2 mg triglycyl-lysin-vasopressin. Following the drug administration, heart rate decreased by 10% and cardiac index by 22% on the average, respectively; mean arterial pressure increased by 14% and systemic vascular resistence index by 48%. Hepatic venous pressure gradient showed a marked and persistent fall, averaging 31%. Hepatic and splenic blood flow decreased by 31% and 56%, respectively. A significant correlation was found between the decrease in hepatic venous pressure gradient and in splenic blood flow. By contrast, the decrease in the hepatic venous pressure gradient was not significantly correlated to the decrease in hepatic blood flow or in cardiac index. We conclude that in patients with alcoholic cirrhosis, triglycyl-lysin-vasopressin decreases portal pressure as well as hepatic and splenic blood flows. The decrease in portal pressure was due to the decrease in splanchnic blood inflow and not to the decrease in cardiac index.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409797     DOI: 10.1007/bf01535785

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

2.  Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal.

Authors:  B M Altura
Journal:  J Pharmacol Exp Ther       Date:  1975-05       Impact factor: 4.030

3.  Splenic blood flow in cirrhosis and portal hypertension.

Authors:  R Williams; R E Condon; H S Williams; L M Blendis; L Kreel
Journal:  Clin Sci       Date:  1968-06       Impact factor: 6.124

4.  Control of bleeding varices by vasopressin: a prospective randomized study.

Authors:  W C Johnson; W C Widrich; J E Ansell; A H Robbins; D C Nabseth
Journal:  Ann Surg       Date:  1977-09       Impact factor: 12.969

5.  [What form of vasopressin to use for the emergency treatment of ruptured esophageal varices?].

Authors:  D Valla
Journal:  Gastroenterol Clin Biol       Date:  1984 Jun-Jul

6.  The effects of intra-arterial and intraportal injections of vasopressin on the simultaneously perfused hepatic arterial and portal venous vascular beds of the dog.

Authors:  P D Richardson; P G Withrington
Journal:  Circ Res       Date:  1978-10       Impact factor: 17.367

7.  Controlled trial of vasopressin and balloon tamponade in bleeding esophageal varices.

Authors:  J Pinto Correia; M Martins Alves; P Alexandrino; J Silveira
Journal:  Hepatology       Date:  1984 Sep-Oct       Impact factor: 17.425

8.  Effect of nadolol on liver haemodynamics and function in patients with cirrhosis.

Authors:  C Merkel; D Sacerdoti; G F Finucci; R Zuin; G Bazzerla; M Bolognesi; A Gatta
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

9.  Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study.

Authors:  S Walker; A Stiehl; R Raedsch; B Kommerell
Journal:  Hepatology       Date:  1986 Jan-Feb       Impact factor: 17.425

10.  Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension.

Authors:  R J Groszmann; D Kravetz; J Bosch; M Glickman; J Bruix; J Bredfeldt; H O Conn; J Rodes; E H Storer
Journal:  Hepatology       Date:  1982 Nov-Dec       Impact factor: 17.425

View more
  4 in total

Review 1.  The use of vasopressin in the treatment of upper gastrointestinal haemorrhage.

Authors:  D L Stump; T C Hardin
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

2.  Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective beta-blocker.

Authors:  F Vachiery; R Moreau; A Gadano; S Yang; P Sogni; A Hadengue; S Cailmail; T Soupison; D Lebrec
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

3.  Matrix metalloproteinase-9 inhibition or deletion attenuates portal hypertension in rodents.

Authors:  Hui-Chun Huang; Hsin-Ling Ho; Ching-Chih Chang; Chiao-Lin Chuang; Chon Kit Pun; Fa-Yauh Lee; Yi-Hsiang Huang; Ming-Chih Hou; Shao-Jung Hsu
Journal:  J Cell Mol Med       Date:  2021-10-14       Impact factor: 5.310

4.  Terlipressin for variceal bleeding induces large plasma sodium fluctuations in patients without cirrhosis.

Authors:  Peter Lykke Eriksen; Anne Luise Hartkopf-Mikkelsen; Peter Ott; Hendrik Vilstrup; Niels Kristian Aagaard
Journal:  United European Gastroenterol J       Date:  2018-05-28       Impact factor: 4.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.